Physician profile
David E Young
NPI 1427069350
$12,055.32
in general payments reported to CMS, 2019-2025
85 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,896 · 2020: $2,544 · 2021: $3,843 · 2022: $974 · 2023: $379 · 2024: $167 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $941.13 | 2019-2024 | Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $762.23 | 2019-2022 | |
| Amgen INC. | $746.99 | 2019-2022 | |
| Astellas Pharma US INC | $624.65 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $572.98 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $544.90 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $461.43 | 2019-2023 | Imbruvica |
| Octapharma USA, INC. | $453.39 | 2019-2020 | |
| Daiichi Sankyo INC. | $400.77 | 2019-2025 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $344.69 | 2019-2021 | |
| Genentech USA, INC. | $330.17 | 2019-2022 | |
| Incyte Corporation | $307.04 | 2019-2022 | |
| Beigene USA, INC. | $260.84 | 2020-2022 | |
| Karyopharm Therapeutics INC. | $249.94 | 2020-2022 | |
| Pfizer INC. | $240.60 | 2019-2022 |
Show all 83 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.